Sionna Therapeutics, Inc. Common Stock (SION) - Net Assets
Based on the latest financial reports, Sionna Therapeutics, Inc. Common Stock (SION) has net assets worth $306.83 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($325.95 Million) and total liabilities ($19.12 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SION cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $306.83 Million |
| % of Total Assets | 94.13% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Sionna Therapeutics, Inc. Common Stock - Net Assets Trend (2022–2025)
This chart illustrates how Sionna Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Sionna Therapeutics, Inc. Common Stock for the complete picture of this company's asset base.
Annual Net Assets for Sionna Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual net assets of Sionna Therapeutics, Inc. Common Stock from 2022 to 2025. For live valuation and market cap data, see SION company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $306.83 Million | +287.42% |
| 2024-12-31 | $-163.71 Million | -42.51% |
| 2023-12-31 | $-114.88 Million | -64.29% |
| 2022-12-31 | $-69.92 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sionna Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18421900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $45.00K | 0.01% |
| Other Comprehensive Income | $540.00K | 0.18% |
| Other Components | $562.60 Million | 183.36% |
| Total Equity | $306.83 Million | 100.00% |
Sionna Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Sionna Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
$1.66 Billion |
|
Shriram Pistons & Rings Limited
NSE:SHRIPISTON
|
$1.66 Billion |
|
Devyani International Limited
NSE:DEVYANI
|
$1.66 Billion |
|
Snowsky Salt Industry Group Co Ltd
SHG:600929
|
$1.66 Billion |
|
Zhejiang CONBA Pharmaceutical Co Ltd
SHG:600572
|
$1.66 Billion |
|
Dis-Chem Pharmacies
JSE:DCP
|
$1.66 Billion |
|
Medicover AB (publ)
ST:MCOV-B
|
$1.66 Billion |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
$1.66 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sionna Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -163,713,000 to 306,833,000, a change of 470,546,000.
- Net loss of 75,268,000 reduced equity.
- New share issuances of 202,071,000 increased equity.
- Other comprehensive income increased equity by 172,000.
- Other factors increased equity by 343,571,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-75.27 Million | -24.53% |
| Share Issuances | $202.07 Million | +65.86% |
| Other Comprehensive Income | $172.00K | +0.06% |
| Other Changes | $343.57 Million | +111.97% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Sionna Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.10x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $-1.58 | $39.15 | x |
| 2023-12-31 | $-2.60 | $39.15 | x |
| 2024-12-31 | $-3.71 | $39.15 | x |
| 2025-12-31 | $7.68 | $39.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sionna Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.06x
- Recent ROE (-24.53%) is below the historical average (-6.13%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-33.25 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-35.77 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-45.32 Million |
| 2025 | -24.53% | 0.00% | 0.00x | 1.06x | $-105.95 Million |
Industry Comparison
This section compares Sionna Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sionna Therapeutics, Inc. Common Stock (SION) | $306.83 Million | 0.00% | 0.06x | $1.66 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109,… Read more